Trial reportBritish journal of cancer2026
Predictive criteria for overall survival and treatment duration of 2nd-line chemotherapy in patients with advanced pancreatic adenocarcinoma (AIO-PAK-0216).
Trial report in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03468335 (Second-line Therapy With Nal-IRI After Failure Gemcitabine/Nab-paclitaxel in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Second-line Therapy With Nal-IRI After Failure Gemcitabine/Nab-paclitaxel in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNot all patients with advanced pancreatic cancer (PC) profit from 2nd-line chemotherapy. We evaluated predictive factors that are routinely collected during clinical care with the aim to support an informed and shared decision.
methodsIn a prospective study across 35 German sites, 151 patients with PC previously treated with gemcitabine/nab-paclitaxel were enrolled and 146 patients received biweekly nanoliposomal irinotecan/5-fluorouracil/FA. We investigated whether time-to-treatment-failure of 1st-line (TTF1) predicts 2nd-line treatment outcome. Patients were stratified into three equal cohorts based on TTF1. Primary endpoint was TTF2, with secondary endpoints including overall survival (OS) and growth modulation index (GMI).
resultsMedian TTF2 was 3.71 months (95% CI 2.50-4.11). Median OS was 7.72 months (95% CI 6.11-9.00). TTF1 did not predict TTF2 or OS (HR 0.93, 95% CI 0.58-1.47. Baseline parameters significantly associated with TTF2 and OS included neutrophil count, CRP levels, and liver metastases, whereas ECOG performance score (PS) was primarily associated with OS and to a lesser extent with TTF2. During treatment, patients with a CA 19-9 reduction of ≥25% had significantly improved TTF2 and OS (p < 0.001).
conclusionTTF1 is not predictive of TTF2 or OS. Therefore, 2nd-line treatment should not be withheld irrespective of duration of TTF1. CA 19-9 dynamics can be used to predict further benefit to some extent. CLINICAL
trial registrationEudraCT: 2016-005147-17; ClinicalTrials.gov: NCT03468335.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.